These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15120337)

  • 1. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.
    Liao X; Li Y; Bonini C; Nair S; Gilboa E; Greenberg PD; Yee C
    Mol Ther; 2004 May; 9(5):757-64. PubMed ID: 15120337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation.
    Schaft N; Dörrie J; Thumann P; Beck VE; Müller I; Schultz ES; Kämpgen E; Dieckmann D; Schuler G
    J Immunol; 2005 Mar; 174(5):3087-97. PubMed ID: 15728524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
    Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
    J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
    Kim CJ; Prevette T; Cormier J; Overwijk W; Roden M; Restifo NP; Rosenberg SA; Marincola FM
    J Immunother; 1997 Jul; 20(4):276-86. PubMed ID: 9220317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells.
    Bontkes HJ; Kramer D; Ruizendaal JJ; Kueter EW; van Tendeloo VF; Meijer CJ; Hooijberg E
    Gene Ther; 2007 Feb; 14(4):366-75. PubMed ID: 17036057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.
    Javorovic M; Wilde S; Zobywalski A; Noessner E; Lennerz V; Wölfel T; Schendel DJ
    J Immunother; 2008 Jan; 31(1):52-62. PubMed ID: 18157012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.
    Grünebach F; Kayser K; Weck MM; Müller MR; Appel S; Brossart P
    Cancer Gene Ther; 2005 Sep; 12(9):749-56. PubMed ID: 15877082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.
    Abdel-Wahab Z; Kalady MF; Emani S; Onaitis MW; Abdel-Wahab OI; Cisco R; Wheless L; Cheng TY; Tyler DS; Pruitt SK
    Cell Immunol; 2003 Aug; 224(2):86-97. PubMed ID: 14609574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
    Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
    Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
    Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.
    Abdel-Wahab Z; Cisco R; Dannull J; Ueno T; Abdel-Wahab O; Kalady MF; Onaitis MW; Tyler DS; Pruitt SK
    J Surg Res; 2005 Apr; 124(2):264-73. PubMed ID: 15820257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
    Tüting T; DeLeo AB; Lotze MT; Storkus WJ
    Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
    Onaitis MW; Kalady MF; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    Surgery; 2003 Aug; 134(2):300-5. PubMed ID: 12947333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer.
    Nencioni A; Müller MR; Grünebach F; Garuti A; Mingari MC; Patrone F; Ballestrero A; Brossart P
    Cancer Gene Ther; 2003 Mar; 10(3):209-14. PubMed ID: 12637942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
    Butterfield LH; Jilani SM; Chakraborty NG; Bui LA; Ribas A; Dissette VB; Lau R; Gamradt SC; Glaspy JA; McBride WH; Mukherji B; Economou JS
    J Immunol; 1998 Nov; 161(10):5607-13. PubMed ID: 9820539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.
    Philip R; Alters SE; Brunette E; Ashton J; Gadea J; Yau J; Lebkowski J; Philip M
    J Immunother; 2000 Jan; 23(1):168-76. PubMed ID: 10687150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
    Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.